Enthera closes Series A at €35 million

Country

Italy

Enthera Pharmaceuticals Srl has closed a Series A financing at €35 million, giving it the resources to bring its lead product for Type 1 diabetes and gastrointestinal diseases into the clinic and develop other assets. The Italian company is developing biologics that are designed to inhibit a protein interaction thought to be critical in the death of beta cells in the pancreas and stem cells in the gut.